MMV533 Plasmodium Falciparum Volunteer Infection Study
Status:
Not yet recruiting
Trial end date:
2022-08-15
Target enrollment:
Participant gender:
Summary
A Phase 1b study to assess the safety, tolerability and antimalarial activity of MMV533
against Plasmodium falciparum 3D7 blood stage infection in healthy volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Medicines for Malaria Venture
Collaborators:
Nucleus Network Ltd Southern Star Research Pty Ltd.